VIVS Organovo: Multiplikator Forward P/S

VivoSim Labs Inc (VIVS) management is adapting 3D bioprinting for the preclinical testing of pharma behemoths, maintaining investor confidence. An ethical approach to research minimizes animal usage, supporting ESG principles. Reviewing the projected P/S changes on GURU.Markets, it is evident that the current status is 16.90, confirming the business's reliability due to a broad network of independent laboratories that reduces biotech financial risks.

Organovo - Rasio kapitalisasi marang dodolan sing dikarepake VIVS (periode 25.04.2025 - 14.11.2026)

Rincian metrik lan analitis perusahaan VivoSim Labs (VIVS)

- rega saiki lan proyeksi nilai saham:

Rega saham Organovo Holdings, Inc.|VIVS - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Kapitalisasi pasar VivoSim Labs|VIVS - Nilai Bisnis

- statistik nilai buku emiten:

Nilai Buku saben Saham Organovo|VIVS - Pambiji Buku Bisnis|Rasio Kapitalisasi Pasar marang Nilai Buku organovo.com|VIVS - Gunggung Aset Perusahaan

- indikator total utang lan likuiditas perusahaan:

- rincian asil keuangan lan kelipatan valuasi:

VIVS - Bathi resik taunan|Bathi mangsa ngarep VivoSim Labs Inc|VIVS - Pangali P/E|Pangali Forward P/E Organovo Holdings|VIVS - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan VivoSim Labs|VIVS - Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Organovo|VIVS - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan organovo.com|VIVS - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep VivoSim Labs Inc

- indikator volume dodolan lan pendapatan:

VIVS - Volume dodolan perusahaan|Volume dodolan mangsa ngarep perusahaan VivoSim Labs|VIVS - Kapitalisasi marang volume dodolan|Multiplikator forward rega marang pendapatan VivoSim Labs

Ringkesan analitik perusahaan:Organovo (VIVS)

Patent protection for bio-inks and FDA certification complexities create significant uncertainty regarding the commercialization timelines for VivoSim Labs Inc (VIVS). By analyzing the expected price-to-sales ratio, an investor can view the current share price relative to projected sales, allowing for an assessment of how much future product success the market has currently priced in and whether it is overpaying for potential growth.

Pesaing wigati

Multiplikator Forward P/S ABT (Abbott)|Thermo Fisher Scientific Inc. (TMO) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|GE Healthcare Corp - Multiplikator Forward P/S|MTD (Mettler Toledo Inc) - Kapitalisasi marang prakiraan pendapatan|WAT: Multiplikator Forward P/S|TECH - Rasio kapitalisasi marang dodolan sing dikarepake|BRKR (Bruker) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Azenta Inc (AZTA)|Multiplikator Forward P/S VREX|Multiplikator Forward P/S Semler (SMLR)|Rasio rega marang prakiraan pendapatan Butterfly Network, Inc. BFLY|mesalabs.com - Rasio rega marang prakiraan pendapatan|QSI: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan NNOX (Nano-X Imaging)|QTRX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep 908 Devices Corporation (MASS)|Rasio rega marang prakiraan pendapatan CapsoVision, Inc.|MXCT - Prakiraan rega marang pendapatan|Multiplikator forward rega marang pendapatan RPID (Rapid Micro Biosystems)|Multiplikator Forward P/S Seer Inc (SEER)|Multiplikator Forward P/S HYPR (Hyperfine Corp)|Rasio kapitalisasi marang dodolan sing dikarepake FONAR Corporation Inc (FONR)|DXR - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan MDAI|Aclarion, Inc. (ACON) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Akoya Biosciences, Inc.|THMO (ThermoGenesis Holdings Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Talis Biomedical Corp TLIS|Rasio rega marang prakiraan pendapatan T2 Biosystems, Inc. (TTOO)